3 years 274.98
Extreme 274.98
503.24
5 years 274.98
Extreme 274.98
805.62
10 years 274.98
Extreme 274.98
948.03
Manager TitleAgeSince
Corporate Secretary 53 21/08/2024
Director TitleAgeSince
Director/Board Member 53 21/08/2024
Date Insider Type Main position Quantity % Market Cap. Importance
21/08/24 Issuer sale

Director

2,991 0.1699%
21/08/24 Issuer sale

Chief Executive Officer

98,614 5.6032%
21/08/24 Issuer sale

Director

499 0.0284%
Change 5-day change 1-year change 3-year change Capi.($)
+0.06%-.--% - - 809M
+1.13%+2.15%-24.87%+2.09% 172B
+0.83%+2.43%-7.30%+16.15% 113B
+0.13%+0.69%-23.94%+1.05% 106B
+2.34%+2.49%-46.47%-11.84% 75.31B
+0.78%+4.79%+1.84%+72.29% 61.8B
+0.12%+3.62%+15.06%+65.87% 52.93B
+0.55%+3.93%-1.51%-31.24% 50.05B
+0.95%-0.08%-15.93%+14.93% 40.81B
+1.45%+1.83% - - 31.81B
Average +0.83%+2.31%-12.89%+16.16% 78.29B
Weighted average by Cap. +0.92%+2.24%-16.31%+12.50%
Logo Atrion Corporation
Atrion Corporation develops and manufactures products, primarily for medical applications. The Company's medical products are used in a number of fields including fluid delivery, cardiovascular, and ophthalmic applications. It has developed a variety of proprietary valves designed to precisely fill, hold, and release and/or remove controlled amounts of fluids, including blood and drugs, or gasses on demand for use in areas such as intubation, intravenous, catheter, and other applications in fields including anesthesia and oncology. The core of its cardiovascular products is its Myocardial Protection System, a technology that is the only open-heart surgery system that delivers to the heart essential fluids and medications, mixes critical drugs, and controls temperature, pressure, and other important variables. The Company also manufactures a line of balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults.
Employees
712
  1. Stock Market
  2. Stocks
  3. ATRI Stock